Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phibro Animal HealthPAHC -3.41%75 5-Year Yield-on-Cost % is 1.39 as of Aug. 08, 2026, which is 29% below its 10-year median of 1.96. GuruFocus rates PAHC with a GF Score™ of 75/100 and a GF Value™ of $29.54 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 513 Drug Manufacturers companies, Phibro Animal Health ranks worse than 66.08% on this metric.
Phibro Animal Health's yield on cost for the quarter that ended in Mar. 2026 was 1.39.
The historical rank and industry rank for Phibro Animal Health's 5-Year Yield-on-Cost % or its related term are showing as below:
PAHC'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.79 Med: 1.96 Max: 4.97
Current: 1.39
During the past 13 years, Phibro Animal Health's highest Yield on Cost was 4.97. The lowest was 0.79. And the median was 1.96.
PAHC's 5-Year Yield-on-Cost % is ranked worse than 66.08% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs PAHC: 1.39
Phibro Animal Health (NAS:PAHC) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Phibro Animal Health 5-Year Yield-on-Cost % Related Terms
PAHC vs PRGO, HROW, XERS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phibro Animal Health 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Phibro Animal Health's 5-Year Yield-on-Cost % falls into.
Phibro Animal Health 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Phibro Animal Health (PAHC) has a 5-Year Yield-on-Cost % of 1.39 as of Aug. 08, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Phibro Animal Health and its competitors. This is 29% below median its historical median of 1.96. Over the past decade, Phibro Animal Health's 5-Year Yield-on-Cost % has ranged from 0.79 to 4.97. According to the industry distribution chart, Phibro Animal Health ranks #339 out of 513 companies in the Drug Manufacturers industry, placing it in the top 66.1%.
Is Phibro Animal Health's 5-Year Yield-on-Cost % too high?
Phibro Animal Health's current 5-Year Yield-on-Cost % of 1.39 is 29% below median its 10-year median of 1.96. Over the past 10 years, this metric has ranged from a low of 0.79 to a high of 4.97. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.29. Phibro Animal Health's value of 1.39 is 39.3% below this industry median. Based on the distribution chart, Phibro Animal Health ranks #339 out of 513 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Phibro Animal Health has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Phibro Animal Health's 5-Year Yield-on-Cost % compare to PRGO and HROW?
According to the Drug Manufacturers industry distribution chart, Phibro Animal Health ranks #339 out of 513 companies for 5-Year Yield-on-Cost %. This places Phibro Animal Health in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.29. Phibro Animal Health's value of 1.39 is 39.3% below this benchmark. Historically, Phibro Animal Health's own 5-Year Yield-on-Cost % has ranged from 0.79 to 4.97 over the past decade. While the company's 10-year median is 1.96 vs. the industry median of 2.29, Phibro Animal Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phibro Animal Health's current 5-Year Yield-on-Cost % of 1.39 is 39.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Phibro Animal Health and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phibro Animal Health's current 5-Year Yield-on-Cost % is 1.39, which is 29% below median its own 10-year median of 1.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phibro Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Phibro Animal Health (PAHC) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.54, compared to a current price of $34.26 — trading 16% above its estimated fair value. The current 5-Year Yield-on-Cost % is 1.39, which is 29% below median its 10-year median of 1.96 and 39.3% below the Drug Manufacturers industry median of 2.29. Phibro Animal Health's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Phibro Animal Health (PAHC), the current 5-Year Yield-on-Cost % is 1.39 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Phibro Animal Health (PAHC) Overvalued in 2026?
Based on GuruFocus' analysis, Phibro Animal Health stock appears to be overvalued.
The current stock price of $34.26 is trading 16% above its estimated GF Value™ of $29.54.
GuruFocus considers Phibro Animal Health to be Modestly Overvalued.
Key valuation signals for PAHC:
5-Year Yield-on-Cost %: 1.39 (29% below median its 10-year median of 1.96)
GF Value™: $29.54 vs. price of $34.26 (16% above fair value)
Industry Position: 39.3% below the Drug Manufacturers median (#339 of 513)
No single metric tells the full story. See the PAHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
75GF Score
Get the complete analysis for PAHC
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PAHC has been successfully added to your 
